Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.
Federico M, Luminari S, Pellegrini C, Merli F, Pesce EA, Chauvie S, Gandolfi L, Capodanno I, Salati M, Argnani L, Zinzani PL. Federico M, et al. Haematologica. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24. Haematologica. 2016. PMID: 26703964 Free PMC article. Clinical Trial. No abstract available.
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.
Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE; Italian Cooperative Group for the Study of Hairy Cell Leukemia. Federico M, et al. J Clin Oncol. 2002 Feb 1;20(3):638-46. doi: 10.1200/JCO.2002.20.3.638. J Clin Oncol. 2002. PMID: 11821443
Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.
Morabito F, Baldini L, Stelitano C, Luminari S, Frassoldati A, Merli F, Colombi M, Sabbatini R, Brugiatelli M, Federico M; Gruppo Italiano per lo studio dei linfomi. Morabito F, et al. Among authors: federico m. Leuk Lymphoma. 2002 Oct;43(10):1933-8. doi: 10.1080/1042819021000016050. Leuk Lymphoma. 2002. PMID: 12481887
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.
Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Zinzani PL, et al. Among authors: federico m. Haematologica. 2002 Dec;87(12):1258-64. Haematologica. 2002. PMID: 12495899 Free article.
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M, Morabito F, Merli F, Molica S, Cavanna L, Sacchi S, Broglia C, Angrilli F, Ilariucci F, Stelitano C, Luisi D, Bertè R, Luminari S, Federico M, Brugiatelli M; GISL. Lombardo M, et al. Among authors: federico m. Leuk Lymphoma. 2002 Sep;43(9):1795-801. doi: 10.1080/1042819021000006457. Leuk Lymphoma. 2002. PMID: 12685834
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.
Baldini L, Brugiatelli M, Luminari S, Lombardo M, Merli F, Sacchi S, Gobbi P, Liberati M, Cavanna L, Colombi M, Stelitano C, Goldaniga M, Morabito F, Federico M, Silingardi V; Gruppo Italiano per lo Studio dei Linfomi. Baldini L, et al. Among authors: federico m. J Clin Oncol. 2003 Apr 15;21(8):1459-65. doi: 10.1200/JCO.2003.07.133. J Clin Oncol. 2003. PMID: 12697867 Clinical Trial.
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias.
Luminari S, Goldaniga M, Ceccherelli F, Guffanti A, Bombardieri E, Marcheselli R, Cro L, Colombi M, Federico M, Baldini L. Luminari S, et al. Among authors: federico m. Br J Haematol. 2003 Jun;121(5):772-4. doi: 10.1046/j.1365-2141.2003.04353.x. Br J Haematol. 2003. PMID: 12780792 Free article.
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM; EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. Federico M, et al. J Clin Oncol. 2003 Jun 15;21(12):2320-5. doi: 10.1200/JCO.2003.11.103. J Clin Oncol. 2003. PMID: 12805333 Clinical Trial.
Splenosis peritonei.
Luminari S, De Santis M, Casolo A, Federico M. Luminari S, et al. Among authors: federico m. Br J Haematol. 2003 Nov;123(3):378. doi: 10.1046/j.1365-2141.2003.04511.x. Br J Haematol. 2003. PMID: 14616993 Free article. No abstract available.
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG, Broglia C, Merli F, Dell'Olio M, Stelitano C, Iannitto E, Federico M, Bertè R, Luisi D, Molica S, Cavalli C, Dezza L, Ascari E. Gobbi PG, et al. Among authors: federico m. Cancer. 2003 Dec 1;98(11):2393-401. doi: 10.1002/cncr.11807. Cancer. 2003. PMID: 14635074 Free article.
778 results